Compile Data Set for Download or QSAR
Report error Found 70 Enz. Inhib. hit(s) with all data for entry = 8720
TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414505(US10435398, Example 19 | N-Ethyl-N-{2-[4-(1-hydrox...)
Affinity DataIC50: 12nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414505(US10435398, Example 19 | N-Ethyl-N-{2-[4-(1-hydrox...)
Affinity DataIC50: 19nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414515(N-(2-(4-(2-Hydroxypropan-2-yl)-5-methyloxazol-2-yl...)
Affinity DataIC50: 19nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414507(N-{2-[4-(1-Hydroxy-1-methylethyl)-5-methyl-1,3-oxa...)
Affinity DataIC50: 19nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414508(N-{2-[4-(1-Hydroxy-1-methylethyl)-5-methyl-1,3-oxa...)
Affinity DataIC50: 19nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414509(N-(Cyclopropylmethyl)-N-{2-[4-(1-hydroxy-1-methyle...)
Affinity DataIC50: 21nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414494(2-(1- cyanocyclopropyl)- N-ethyl-N-{2-[4-(1- hydro...)
Affinity DataIC50: 26nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414497(US10435398, Example 11 | N-Ethyl-N-{2-[4-(1-hydrox...)
Affinity DataIC50: 27nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414483(N-Ethyl-N-(2-(4-(2-hydroxypropan-2-yl)-5-methyloxa...)
Affinity DataIC50: 29nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414518(N-Cyclobutyl-N-(2-(4-(2-hydroxypropan-2-yl)-5-meth...)
Affinity DataIC50: 38nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414517(N-Cyclopropyl-N-(2-(4-(2-hydroxypropan-2-yl)-5-met...)
Affinity DataIC50: 42nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414485(N-Ethyl-3-fluoro-N- {2-[4-(1-hydroxy-1- methylethy...)
Affinity DataIC50: 44nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414486(N-Ethyl-4-fluoro-N- {2-[4-(1-hydroxy-1- methylethy...)
Affinity DataIC50: 48nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414484(N-Ethyl-N-{2-[4-(1- hydroxy-1- methylethyl)-5- met...)
Affinity DataIC50: 54nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414490(N-Ethyl-5-fluoro-N- {2-[4-(1-hydroxy-1- methylethy...)
Affinity DataIC50: 62nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414498(N-Ethyl-N-{2-[4-(1-hydroxy- 1-methylethyl)-5-methy...)
Affinity DataIC50: 63nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414511(N-(2,2-Difluoroethyl)-N-{2-[4-(1-hydroxy-1-methyle...)
Affinity DataIC50: 68nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414491(N-Ethyl-N-{2-[4-(1- hydroxy-1- methylethyl)-5- met...)
Affinity DataIC50: 82nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414499(N-Ethyl-N-{2-[4-(1-hydroxy- 1-methylethyl)-5-methy...)
Affinity DataIC50: 98nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414514(N-(2-hydroxyethyl)-N-(2-(4-(2-hydroxypropan-2-yl)-...)
Affinity DataIC50: 98nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414489(N-Ethyl-N-{2-[4-(1- hydroxy-1- methylethyl)-5- met...)
Affinity DataIC50: 101nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414519(N-(2-(4-(2-Hydroxypropan-2-yl)-5-methyloxazol-2-yl...)
Affinity DataIC50: 119nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414504(2-(1-(difluoro- methyl)cyclopropyl)- N-ethyl-N-(2-...)
Affinity DataIC50: 145nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414497(US10435398, Example 11 | N-Ethyl-N-{2-[4-(1-hydrox...)
Affinity DataIC50: 152nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414500(N-Ethyl-N-{2-[4-(1-hydroxy- 1-methylethyl)-5-methy...)
Affinity DataIC50: 211nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414495(N-ethyl-N-{2-[4-(1- hydroxy-1- methylethyl)-5- met...)
Affinity DataIC50: 212nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414501(2-Ethoxy-N-ethyl-N-{2-[4-(1- hydroxy-1-methylethyl...)
Affinity DataIC50: 223nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414493(2-(2,2- difluoroethoxy)-N- ethyl-N-{2-[4-(1- hydro...)
Affinity DataIC50: 224nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414503(N-Ethyl-N-{2-[4-(1-hydroxy- 1-methylethyl)-5-methy...)
Affinity DataIC50: 292nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414513(N-{2-[4-(1-Hydroxy-1-methylethyl)-5-methyl-1,3-oxa...)
Affinity DataIC50: 304nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414487(2-Cyclopropyl-N- ethyl-N-{2-[4-(1- hydroxy-1- meth...)
Affinity DataIC50: 387nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414516(N-(2-(4-(2-Hydroxypropan-2-yl)-5-methyloxazol-2-yl...)
Affinity DataIC50: 390nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414496(N-ethyl-N-{2-[4-(1- hydroxy-1- methylethyl)-5- met...)
Affinity DataIC50: 435nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414492(N-ethyl-N-{2-[4-(1- hydroxy-1- methylethyl)-5- met...)
Affinity DataIC50: 491nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414502(Methyl 2-(ethyl{2-[4-(1- hydroxy-1-methylethyl)-5-...)
Affinity DataIC50: 630nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414507(N-{2-[4-(1-Hydroxy-1-methylethyl)-5-methyl-1,3-oxa...)
Affinity DataIC50: 1.01E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414494(2-(1- cyanocyclopropyl)- N-ethyl-N-{2-[4-(1- hydro...)
Affinity DataIC50: 1.76E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414483(N-Ethyl-N-(2-(4-(2-hydroxypropan-2-yl)-5-methyloxa...)
Affinity DataIC50: 1.83E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414508(N-{2-[4-(1-Hydroxy-1-methylethyl)-5-methyl-1,3-oxa...)
Affinity DataIC50: 2.37E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414497(US10435398, Example 11 | N-Ethyl-N-{2-[4-(1-hydrox...)
Affinity DataIC50: 2.59E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414505(US10435398, Example 19 | N-Ethyl-N-{2-[4-(1-hydrox...)
Affinity DataIC50: 2.67E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414509(N-(Cyclopropylmethyl)-N-{2-[4-(1-hydroxy-1-methyle...)
Affinity DataIC50: 2.84E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414505(US10435398, Example 19 | N-Ethyl-N-{2-[4-(1-hydrox...)
Affinity DataIC50: 3.38E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414517(N-Cyclopropyl-N-(2-(4-(2-hydroxypropan-2-yl)-5-met...)
Affinity DataIC50: 7.59E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414518(N-Cyclobutyl-N-(2-(4-(2-hydroxypropan-2-yl)-5-meth...)
Affinity DataIC50: 8.18E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414503(N-Ethyl-N-{2-[4-(1-hydroxy- 1-methylethyl)-5-methy...)
Affinity DataIC50: 1.00E+4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414504(2-(1-(difluoro- methyl)cyclopropyl)- N-ethyl-N-(2-...)
Affinity DataIC50: 1.00E+4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414501(2-Ethoxy-N-ethyl-N-{2-[4-(1- hydroxy-1-methylethyl...)
Affinity DataIC50: 1.00E+4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414502(Methyl 2-(ethyl{2-[4-(1- hydroxy-1-methylethyl)-5-...)
Affinity DataIC50: 1.00E+4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM414499(N-Ethyl-N-{2-[4-(1-hydroxy- 1-methylethyl)-5-methy...)
Affinity DataIC50: 1.00E+4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/16/2020
Entry Details
US Patent

Displayed 1 to 50 (of 70 total ) | Next | Last >>
Jump to: